Vir Biotechnology Inc [NASDAQ: VIR] traded at a high on 2025-08-27, posting a 17.79 gain after which it closed the day’ session at $5.23.
The results of the trading session contributed to over 7388209 shares changing hands. Over the past one week, the price volatility of Vir Biotechnology Inc stands at 7.86% while the volatility over the past one month is 5.65%.
The market cap for VIR stock reached $726.53 million, with 138.89 million shares outstanding and 89.57 million shares in the current float. Compared to the average trading volume of 1.18M shares, VIR reached a trading volume of 7388209 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Vir Biotechnology Inc [VIR]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for VIR shares is $17.88 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on VIR stock is a recommendation set at 1.22. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BofA Securities have made an estimate for Vir Biotechnology Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on August 27, 2025. While these analysts kept the previous recommendation, JP Morgan raised their target price from $23 to $9. The new note on the price target was released on January 29, 2024, representing the official price target for Vir Biotechnology Inc stock. Previously, the target price had yet another drop from $23 to $14, while BofA Securities kept a Neutral rating on VIR stock. On March 06, 2023, analysts decreased their price target for VIR shares from 35 to 34.
The Price to Book ratio for the last quarter was 0.77, with the Price to Cash per share for the same quarter was set at 5.00.
How has VIR stock performed recently?
Vir Biotechnology Inc [VIR] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 19.95. With this latest performance, VIR shares dropped by -0.38% in over the last four-week period, additionally sinking by -43.15% over the last 6 months – not to mention a drop of -28.75% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for VIR stock in for the last two-week period is set at 60.32, with the RSI for the last a single of trading hit 0.35, and the three-weeks RSI is set at 0.31 for Vir Biotechnology Inc [VIR]. The present Moving Average for the last 50 days of trading for this stock 5.09, while it was recorded at 4.60 for the last single week of trading, and 6.83 for the last 200 days.
Vir Biotechnology Inc [VIR]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Vir Biotechnology Inc [VIR] shares currently have an operating margin of -2961.64% and a Gross Margin at 35.21%. Vir Biotechnology Inc’s Net Margin is presently recorded at -2895.94%.
Vir Biotechnology Inc (VIR) Capital Structure & Debt Analysis
According to recent financial data for Vir Biotechnology Inc. ( VIR), the Return on Equity (ROE) stands at -46.22%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -38.45%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Vir Biotechnology Inc’s Return on Invested Capital (ROIC) is -52.86%, showcasing its effectiveness in deploying capital for earnings.
Vir Biotechnology Inc (VIR) Efficiency & Liquidity Metrics
Based on Vir Biotechnology Inc’s (VIR) latest financial statements, the Debt-to-Equity Ratio is 0.11%, indicating its reliance on debt financing relative to shareholder equity.
Vir Biotechnology Inc (VIR) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Vir Biotechnology Inc. (VIR) effectively leverages its workforce, generating an average of -$1348602.94 per employee. The company’s liquidity position is robust, with a Current Ratio of 7.01% and a Quick Ratio of 7.01%, indicating strong ability to cover short-term liabilities.
Earnings analysis for Vir Biotechnology Inc [VIR]
With the latest financial reports released by the company, Vir Biotechnology Inc posted -1.56/share EPS, while the average EPS was predicted by analysts to be reported at -1.08/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -0.48. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for VIR. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Vir Biotechnology Inc go to 14.54%.
Insider trade positions for Vir Biotechnology Inc [VIR]
There are presently around $81.80%, or 91.40%% of VIR stock, in the hands of institutional investors. The top three institutional holders of VIR stocks are: SB INVESTMENT ADVISERS (UK) LTD with ownership of 16.68 million shares, which is approximately 12.2466%. BLACKROCK INC., holding 16.43 million shares of the stock with an approximate value of $$146.26 million in VIR stocks shares; and BLACKROCK INC., currently with $$114.36 million in VIR stock with ownership which is approximately 9.4317%.
